Table 3.
Synthesis of the diagnostic performance of studies which explored the performance of Quidel Sofia SARS antigen Fluorescent Immunoassay (FIA) for diagnosing acute SARS-CoV-2 infections and ought to be excluded from the meta-analysis due to unavailability of data for constructing a 2x2 table
| Authors | Cohort | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|
| Agard et al., 2022 [34] | Low-risk | 0.26 (-) | 1.00 (-) |
| Agard et al., 2022 [34] | High-risk | 0.37 (-) | 1.00 (-) |
| Al-Alawi et al., 2021 [35] | Symptomatic patients | 0.64 (0.50-0.77) | 0.97 (0.95-0.98) |
| Brihn et al., 2021 [36] | Asymptomatic patients | 0.60 (0.50-0.71) | 1.00 (0.99-1.00) |
| Brihn et al., 2021 [36] | Symptomatic patients | 0.72 (0.61-0.83) | 0.99 (0.97-1.00) |
| Schroeder et al., 2022 [37] | Asymptomatic patients | 0.60 (0.45-0.71) | - |
| Schroeder et al., 2022 [37] | Symptomatic patients | 0.77 (0.56.-0.85) | - |